Suppr超能文献

静脉空化消融术治疗慢性静脉疾病的创新技术:概念验证和离体分析。

Empty vein ablation innovative technique for chronic venous disease treatment: proof of concept and ex-vivo analysis.

机构信息

Unit of Angiology, Department of Medicine and Cardiopulmonary Rehabilitation, IRCCS Maugeri Institute, Tradate, Varese, Italy.

I-VASC S.r.l, Milan, Italy.

出版信息

Int Angiol. 2023 Oct;42(5):420-426. doi: 10.23736/S0392-9590.23.05055-1. Epub 2023 Jun 28.

Abstract

BACKGROUND

Sclerotherapy is among the mainstays of chronic venous disease treatment, yet its occlusion rate remains suboptimal compared to thermal tumescent techniques. An innovative three-balloons catheter has been developed to allow sclerotherapy in empty vein conditions (empty vein ablation technique, EVA). Aim of this investigation was to describe the EVA technical aspects and related ex-vivo effects on vein wall.

METHODS

Two samples from jugular veins of an adult sheep were treated by EVA or foam sclerotherapy (FS, Tessari method). Primary outcome was the percentage of circumferential intima treated by EVA or FS; secondary outcomes were intima and media thickness modifications after treatment.

RESULTS

Intact circumferential residual intima were 6.07±2.94% and 16.55±0.70% after EVA and FS, respectively (P=0.020). Despite the average intima and media thickness did not differ between treatments, EVA demonstrated a homogenous damage throughout the vein segment, while FS effect was less destructive distally to the injection site, because moving away from the injection site and floating, it has a less contact with internal surface of the vein.

CONCLUSIONS

EVA seems to overcome chemical ablation limits as flushing effect and the increases vein wall/sclerosant agent contact effect compared to FS. Ex-vivo encouraging results need in-vivo validation to evaluate other points like deactivation of sclerosing agent by blood protein and the contact time control between SA and the vein wall. If we have further confirmations in vivo we might think we have a potential higher occlusion rate compared to FS, paving the way for future clinical trials.

摘要

背景

硬化疗法是慢性静脉疾病治疗的主要方法之一,但与热肿胀技术相比,其闭塞率仍不理想。一种创新的三球囊导管已被开发出来,以允许在空静脉条件下进行硬化疗法(空静脉消融技术,EVA)。本研究的目的是描述 EVA 的技术方面及其对静脉壁的相关离体效果。

方法

用 EVA 或泡沫硬化疗法(FS,Tessari 法)处理来自成年绵羊颈静脉的两个样本。主要结果是 EVA 或 FS 处理的周向内膜百分比;次要结果是治疗后内膜和中膜厚度的变化。

结果

EVA 和 FS 后完整的周向残留内膜分别为 6.07±2.94%和 16.55±0.70%(P=0.020)。尽管两种治疗方法的内膜和中膜平均厚度没有差异,但 EVA 显示出整个静脉段的均匀损伤,而 FS 效应在注射部位远端的破坏性较小,因为远离注射部位和漂浮,它与静脉内部表面的接触较少。

结论

EVA 似乎克服了化学消融的限制,如冲洗效应和增加了静脉壁/硬化剂的接触效应,与 FS 相比。离体的令人鼓舞的结果需要在体内进行验证,以评估其他因素,如血液蛋白对硬化剂的失活作用以及 SA 与静脉壁之间的接触时间控制。如果我们在体内得到进一步的证实,我们可能会认为与 FS 相比,我们有更高的闭塞率的潜力,为未来的临床试验铺平了道路。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验